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Aim: To examine the effect of Ankaferd Blood Stopper (ABS) on bone healing using a rat femur fracture model.
Materials and methods: Eight rats were used as a control group (group 1), which was not subjected to fractures. The remaining 48 rats
were divided into 6 groups of 8 each. The femoral shaft fractures were produced by cutting with bone scissors. One milliliter of ABS was
applied to the fracture region of groups 3 (day 7), 5 (day 21), and 7 (day 45), or rats treated with saline instead of ABS on the fracture
region in groups 2 (day 7), 4 (day 21), and 6 (day 45). After the treatments, blood was taken for analyses and fracture healing was
evaluated radiologically according to the modified Lane and Sandhu scoring system on postfracture days 7, 21, and 45.
Results: Fracture-hematoma formation interfered with ABS-induced hemostatic protein network or aggregation. Radiological healing
scores observed at an average of 50% in group 3 were low compared to group 2 the first week, but fracture healing seemed to be normal at
weeks 3 and 6. No statistical difference was observed for bone morphogenetic protein-2 and fibroblast growth factor-2 (FGF-2), alkaline
phosphatase, osteocalcin, pyridinoline, and deoxypyridinoline studied among the groups. FGF-2 level in serum decreased by an average
of 37.3% and 32.6% in groups 3 and 7, which were treated with ABS, in comparison with groups 2 and 6, respectively.
Conclusion: The application of ABS to femur fractures has no extra positive effect on bone union in fracture healing periods, except
for bleeding control.
Key words: Ankaferd, fracture healing, BMP-2, FGF-2, bone formation, resorption markers

1. Introduction
The control of the injured bone or fracture and
surrounding tissue bleeding during orthopedic surgery
can sometimes be challenging and time-consuming for
surgeons. Hemostatic agents such as bone wax, Surgicel,
Ostene, fibrin glue, and Ankaferd Blood Stopper (ABS) are
frequently used in medicinal and dental surgery to control
bleeding at diverse body sites (1,2). From these, ABS, an
herbal extract used as a hemostatic agent, is a medicinal
remedy for clinical management of surgery bleedings as
well as immediate cessation of bleeding of external injuries
based on upcoming clinical trials (3–5; www.ankaferd.
com).
On the other hand, the fracture healing process
includes initial hematoma formation, which is followed by
inflammation, repair, and finally remodeling. The biological
processes that take place during each of these stages are
tightly controlled by signaling molecules, which may be
classified into proinflammatory cytokines, transforming
growth factor-beta (TGF-β) members and other growth
differentiation factors, and the angiogenic factors (6–8).
* Correspondence: aramazan@omu.edu.tr

Bone morphogenetic proteins (BMPs), which belong to
the TGF-β superfamily, have been implicated in a variety
of functions including the formation of both cartilage and
bone in skeletal embryogenesis and to be osteoinductive in
vitro and in vivo (9). From these BMPs, BMP-2 is produced
by mesenchymal cells, osteoblasts, and chondrocytes
during fracture healing. BMP-2 is absolutely required
for normal fracture healing (9,10). FGF-2 is recognized
as a potent mitogen for a variety of mesenchymal cells.
In bone fractures, FGF-2 is produced by mesenchymal
cells, osteoblasts, osteocytes, chondrocytes, periosteal
cells, and monocytes and macrophages. It is an important
modulator of cartilage and bone cell function. Both BMP2 and FGF-2 take part in processes from inflammation to
the remodeling stage in fracture healing (11–13).
Markers of bone formation (e.g., alkaline phosphatase
[ALP], osteocalcin [OC]) and resorption (e.g., pyridinoline
[PYD], deoxypyridinoline [DPYD]) reflect the overall
osteoblastic and osteoclastic activity in the skeleton
(14,15). As biomarkers of bone turnover, they clinically
provide useful evidence of the normal and pathologic
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processes reflecting bone metabolism or cell activity in the
bone tissues (16).
The present study evaluates the changes in serum
growth factors (e.g., BMP-2, FGF-2) and markers relating
to bone formation and resorption during fracture healing
in the absence and presence of ABS in a rat femur fracture
model. In addition, we also examine the effectiveness of
ABS on bone union after ABS application to the fracture
region.
2. Materials and methods
The study had the approval of the local ethics committee
for animal studies. This study was performed in the
Experimental Research Center of Ondokuz Mayıs
University, Samsun, Turkey. A total of 56 Sprague Dawley
male rats, weighing 250–300 g, were allowed to adapt to
the laboratory environment for 1 week before the onset of
the experiment. They were permitted to take water and a
standard laboratory diet. The rats were kept in a room at a
constant temperature of 22 ± 1 °C in individual cages.
2.1. Animal treatment
To determine the basal BMP-2, FGF-2, ALP, OC, PYD,
and DPYD levels of blood, specimens were taken from 8
rats that had not been subjected to fracture of the femur,
and these rats were not treated with ABS or 0.9% NaCl
(group 1, control group). The remaining 48 rats were
divided into 6 groups of 8 animals each representing days
7, 21, and 45 after fracture. Experimental group rats were
anesthetized with 50 mg/kg ketamine (Ketalar, Pfizer,
Turkey) and 10 mg/kg xylazine (Rompun, Bayer, Turkey).
When the appropriate depth of anesthesia had been
achieved, fractures were produced with a minimal open
method in the experimental groups. To do this, an anterior
incision was made to the femur and knee joints. Exposing
the femur condyles, a 1-mm Kirschner wire was employed
to make an opening of the medullar canal placed into the
femur. After Kirschner wire placement to the medullar
canal of the femur, the bone was cut with bone scissors.
Standardized ABS ampoules of 2 mL (patent number
2007-906002) were supplied free of charge from Ankaferd
Drug Inc., İstanbul, Turkey. One milliliter of ABS was
applied to the fracture region of groups 3 (day 7), 5 (day
21), and 7 (day 45) before closure of the surgical area, while
saline instead of ABS was applied to the fracture region of
groups 2 (day 7), 4 (day 21), and 6 (day 45) before closure
of the surgical area. Rats were followed for 7, 21, and 45
days after fracture. At the end of experimental periods,
radiographs of the femur were taken under anesthesia at
weeks 1, 3, and 6 after fracture operation. The Lane and
Sandhu (17) method was used for radiological scoring
system on fracture union with or without ABS application.
All radiographs were evaluated by an orthopedic surgeon
using the radiologic criteria with respect to the modified

734

Lane and Sandhu method. After blood specimens were
obtained by direct intracardiac puncture with an injector
for assays, all rats were sacrificed by exsanguinations
under anesthesia.
2.2. Biochemical assays
Circulating BMP-2, FGF-2, ALP, OC, PYD, and DPYD
levels were measured with ELISA kits (USCN rat BMP-2
[cat. no: E0013Ra], USCN rat FGF-2 [cat. no: E0551Ra],
USCN rat ALP [cat. no: E1091Ra], USCN rat OC [cat. no:
E0471Ra], CSB rat PYD [cat. no: E11870r], and CSB rat
DPYD [cat. no: E08400r]) in the serum samples.
2.3. Statistical analysis
Data were analyzed by the Shapiro-Wilk test for normal
distribution of the quantitative outcomes. They were not
normally distributed. Therefore, nonparametric statistical
analyses were used for all comparisons. The Kruskal–Wallis
test was used to determine the statistical significance of the
differences in the groups. The Mann–Whitney U test (with
Bonferroni correction) was then used for comparisons
between the groups. P < 0.05 was taken as statistically
significant.
3. Results
The Figure represents the control of the fracture and
surrounding tissue bleeding after ABS application to femur
fracture. In addition to this, fracture-hematoma formation
seems to have declined. The findings of radiologic fracture
healing scores observed at an average of 50% in group 3
treated with ABS were low with respect to group 2 at the
end of first week. However, statistical analysis showed
that there was no significant difference between median
radiological healing scores of the groups on postfracture
days 7, 21, and 45 (Table 1).
Changes in BMP-2, FGF-2, markers of bone formation
(ALP, OC), and resorption (PYD, DPYD) levels following
femur fractures in all groups are shown in Tables 2 and 3.

Figure. A photograph after the application of ABS on rat femur
fracture (←) area.
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BMP-2 levels in serum were slightly increased in groups
6 and 7 at week 6 after fracture. The serum values of
FGF-2 were raised during fracture healing without ABS
application at weeks 1, 3, and 6 with respect to the control
(baseline). Its level was decreased by a median of 37.3%
and 32.6% in groups 3 and 7 treated with ABS compared
to groups 2 and 6, respectively. Serum ALP levels were
slightly increased in fracture healing periods after fracture.
OC levels fluctuated during fracture healing in the serum
of all experimental animals. No statistical difference was
observed for PYD and DPYD studied among the groups.
However, DPYD was measured high at a median of 34.3%
in serum of rats treated with ABS at week 6 according to
group 6.
4. Discussion
ABS, which is a standardized hemostatic agent, comprises a
mixture of plants: Thymus vulgaris, Glycyrrhiza glabra, Vitis
vinifera, Alpinia officinarum, and Urtica dioica. Besides its
hemostatic activity, it possesses antiinflammatory actions,
antimicrobial activity, antithrombin, antiplatelet, wound
healing, and antioxidant characteristics, and antineoplastic
properties in vitro, and it does not exhibit any side effects
(1,3,5,18,19).
Application of ABS in tampon forms, sprays, and
solutions has the therapeutic potential to be used for
the management of external postsurgical bleedings and
hemorrhages in medical and dental clinics in Turkey
(18). In recent years, ABS has been used experimentally
in medical orthopedic areas such as pelvis fracture and
shoulder prosthesis operations, knee-ankle-foot orthosis,
vertebral column (backbone) surgery, the control of
sternal bleeding, the management of hemarthrosis,
femur fracture, and tibia defect models (1,5,18–20; www.
ankaferd.com). In relation to this issue, İşler et al. (19)
indicated that the application of ABS to tibia defects
decreased the occurrence of inflammation and necrosis
in the early bone healing period. Recently, Amanvermez
et al. (20) reported that the values of proinflammatory

cytokines (e.g., TNF-α, IL-1β) were elevated in the
postfracture first week according to the control (baseline),
but circulating levels of these cytokines were found to be
low after Ankaferd application to the fracture region. In
addition, radiological examination indicated a low callus
formation on fracture union in the femur fractures treated
with ABS in the early fracture healing period. Normally,
bone fracture is an injury, and thus inflammation is an
immediate response to bone injury. In fracture-hematoma,
following injury, disruption of blood vessels leads to
activation of the coagulation cascade and formation of a
hematoma, which encloses the fracture area. Hematoma is
the source of signaling molecules that have the capacity to
initiate the cascades of cellular events, which are critical to
fracture healing. Removal of the hematoma significantly
attenuates fracture repair as well. A growing body of
evidence indicates that the signaling cascades initiated
during the week-long acute inflammatory response plays
an essential role in healing after fracture (21,22). Thus,
fracture-hematoma and inflammation are required for
fracture healing.
The control of bleeding after ABS application to
the fracture region is shown in the Figure. Fracturehematoma formation, as seen in the Figure, appeared to
decline after ABS application; hematoma formation most
likely interferes with the ABS-induced hemostatic protein
network or aggregation. In other words, radiologic fracture
healing scores were low, observed at an average of 50% in
group 3 treated with ABS with respect to group 2 at the
first week (Table 1). As a result of these findings, removal
of the fracture-hematoma or lesser hematoma formation
and inflammation suppressed by ABS application on the
first days may have resulted in delayed union in fracture
healing.
There was no significant difference in healing scores in
groups treated and untreated with ABS at weeks 3 and 6 in
the view of fracture union, according to radiologic findings.
It is noteworthy that ABS application has no adverse effect
on total bone fracture healing. Therefore, ABS can be used

Table 1. Statistical findings of the study groups radiologically.
Groups

Control (n = 8)

ABS (n = 8)

P

Day 7 fracture healing
Median (min–max)

2 (1–3)

1 (1–3)

>0.05

Day 21 fracture healing
Median (min–max)

2 (1–3)

2 (1–3)

>0.05

Day 45 fracture healing
Median (min–max)

3 (3–4)

3 (0–4)

>0.05

The Lane and Sandhu radiological system was used, which scores fracture healing as (0): nonunion, (1): callus formation, (2): initiation
of bone union, (3): beginning of disappearance of fracture line, (4): complete bone union.
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Table 2. The serum values of BMP-2 and FGF-2 during fracture healing with or without ABS in all groups.
Parameters

Groups
(n = 8)

BMP-2 (ng/mL)

FGF-2 (pg/mL)

1- Control (baseline)

0.74 (0.70–0.80)

11.31 (7.33–27.97)

2- Day 7 fracture healing
3- ABS + day 7 fracture healing

0.75 (0.72–0.86)
0.73 (0.70–0.90)

21.62 (7.33–68.09)
13.55 (2.04–29.79)

4- Day 21 fracture healing
5- ABS + day 21 fracture healing

0.73 (0.70–0.81)
0.72 (0.69–0.86)

13.99 (5.56–27.06)
15.34 (9.99–78.68)

6- Day 45 fracture healing
7- ABS + day 45 fracture healing

0.81 (0.76–0.91)
0.80 (0.73–0.90)

23.43 (12.66–57.60)
15.78 (8.22–39.89)

Data are expressed as median (min–max). BMP-2: bone morphogenetic protein-2, FGF-2: fibroblast growth factor-2.

Table 3. The serum levels of ALP, OC, PYD, and DPYD during fracture healing with or without ABS in all groups.

Groups
(n = 8)

Parameters
ALP
(U/L

OC
(ng/mL)

PYD
(ng/mL)

DPYD
(pmol/mL)

1-Control (baseline)

9.95 (8.33–12.35)

6.26 (3.94–9.73)

1.56 (1.18–4.42)

2.50 (1.76–3.95)

2- Day 7 fracture healing
3- ABS + day 7 fracture healing

11.42 (9.77–14.61)
11.79 (11.24–14.2)

6.70 (4.43–8.66)
5.43 (3.94–8.79)

1.56 (1.22–2.99)
1.67 (1.12–2.07)

2.46 (1.94–5.98)
2.27 (1.07–3.34)

4- Day 21 fracture healing
5- ABS + day 21 fracture healing

10.50 (8.69–11.98)
11.05 (9.77–11.90)

5.87 (4.56–6.96)
6.13 (4.06–7.09)

3.10 (1.34–5.01)
1.66 (1.34–3.12)

3.55 (1.99–5.73)
3.22 (1.27–7.18)

6- Day 45 fracture healing
7- ABS + day 45 fracture healing

10.13 (9.41–15.77)
11.97 (9.41–14.61)

4.55 (4.31–7.48)
5.62 (3.94–6.96)

2.25 (1.33–3.48)
2.97 (1.49–4.54)

2.89 (2.09–5.45)
4.40 (3.79–5.42)

Data are expressed as median (min–max). ALP: alkaline phosphatase, OC: osteocalcin, PYD: pyridinoline, DPYD: deoxypyridinoline.

safely in a number of hemostatic bleeding disorders and to
control intraoperative and postoperative bleedings, and to
obtain surgical comfort in dental and orthopedic clinics.
During bone healing, fibroblast growth factors
(FGF-1, FGF-2) promote growth and differentiation of a
variety of cells like fibroblasts, myocytes, osteoblasts, and
chondrocytes (8). FGF-1 and FGF-2 are identified during
the early stages of fracture healing. They play an important
role in angiogenesis and mesenchymal cell mitogenesis.
FGF-1 is important for chondrocyte proliferation and
maturation, while FGF-2 is expressed by osteoblasts
and is usually more potent than FGF-1 (8,12,13). In
this study, serum FGF-2 levels measured at weeks 1, 3,
and 6 during fracture healing were high with respect to
control (baseline). However, FGF-2 levels decreased by
an average of 37.3% and 32.6% in groups 3 and 7 treated
with ABS, compared to groups 2 and 6, respectively.
According to this finding, it may be suggested that FGF-2
expression may negatively affect fracture healing after the
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administration of ABS. BMPs induce a sequential cascade
of events for chondro-osteogenesis, including chemotaxis,
mesenchymal and osteoprogenitor cell proliferation and
differentiation, angiogenesis, and controlled synthesis of
extracellular matrix (13). For instance, BMP-2/4 causes
precursor cells to become chondroblasts during fracture
healing and express the proteins needed for production of
woven bone (23). In this study, serum BMP-2 levels were
slightly raised at week 6 according to the other groups.
In order to determine the markers of bone formation
and resorption in fracture healing periods with or without
Ankaferd, we also examined the serum levels of ALP, OC,
PYD, and DPYD, respectively. All of these serum markers
increased or decreased after different skeletal bone fractures
and fluctuated during fracture healing in agreement with
the literature data (14,24–26). For example, OC elevated
at 24 weeks after fracture of the tibial shaft and rose at 1
week after distal radial fracture. ALP increased at 4 weeks
after fracture of the tibial shaft and remained elevated at 1
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year (26). PYD-DPYD peaks 1 to 8 weeks after proximal
femoral fracture, and PYD peaks 1 to 4 weeks after
fracture of the tibial shaft. PYD is a less specific marker
of bone resorption than DPYD since it is abundant in all
connective tissues; however, DPYD is distributed generally
in bone and dentin, and 90% of the bone matrix consists of
type I collagen (14,26). In the present study, no significant
changes were observed for the markers of bone formation
and resorption analyzed between the groups.
In conclusion, the application of ABS to the fracture
region resulted in bleeding control. However, fracturehematoma formation interferes with ABS-induced
hemostatic protein network or aggregation. Additionally,
the application of ABS to the fracture area in the presence
of femur fracture led to reduced radiologic fracture
healing scores at the first week of fracture healing, except

for weeks 3 and 6. FGF-2 level in serum decreased by a
median of 37.3% and 32.6% in groups 3 and 7 treated
with ABS as compared to groups 2 and 6, respectively. It
may be suggested that, based on the present findings, ABS
application to femur fracture has no extra positive effect
on fracture healing process. However, further studies
with a larger number of animals are necessary to confirm
benefits or possible adverse effects of the ABS application
on fracture healing, including growth factor expressions
and pathological data of fracture area in fracture healing
periods.
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